MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext...
MONT-SAINT-GUIBERT, Belgium, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage...
First ever morphologic complete response (MLFS1) with gene-engineered T cells without prior...
MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext...
Celyad’s management will host a conference call at 2pm CEST / 8am EDT today Strong progress in THINK...
Ongoing clinical trial development boosts Celyad’s confidence in the future of its oncology assetsCelyad to...
SHRINK study to evaluate the synergetic effect of the concurrent administration of CYAD-01 (CAR-T NKG2D...
Review of NKR-2 pre-clinical work published in Future Oncology In vitro efficacy on various cancer models...
MONT-SAINT-GUIBERT, Belgium, May 30, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.